Fulgent Genetics (FLGT) Cash & Current Investments (2015 - 2026)

Fulgent Genetics has disclosed Cash & Current Investments across 12 years of filings, most recently posting $257.0 million for Q2 2026.

• In Q2 2026, Cash & Current Investments fell 12.25% year-over-year to $257.0 million; the TTM figure through Jun 2026 stood at $257.0 million (down 12.25% YoY), while the FY2025 annual figure was $336.1 million, up 30.21% from the prior year.
• Cash & Current Investments came in at $257.0 million for Q2 2026 at Fulgent Genetics, down from $276.3 million in the prior quarter.
• In the past five years, Cash & Current Investments ranged from a high of $585.1 million in Q1 2022 to a low of $213.1 million in Q3 2024.
• Average Cash & Current Investments over 5 years is $388.9 million, with a median of $355.9 million recorded in 2025.
• Year-over-year, Cash & Current Investments tumbled 54.45% in 2024 and surged 76.38% in 2025.
• Over 5 years, Cash & Current Investments stood at $526.2 million in 2022, then decreased by 19.4% to $424.2 million in 2023, then sank by 39.15% to $258.1 million in 2024, then surged by 30.21% to $336.1 million in 2025, then slipped by 23.52% to $257.0 million in 2026.
• Per Business Quant data, the three most recent Cash & Current Investments figures were $257.0 million in Q2 2026, $276.3 million in Q1 2026, and $336.1 million in Q4 2025.